CTOs on the Move

FEI Systems

www.feisystems.com

 
FEI Systems is a leading IT company specializing in Federal and Local Government data system solutions, and for the past decade we have maintained a leading position in providing programming and consulting services in our primary areas of expertise- Behavioral Health Data Systems, and Clinical Trials Software Solutions for institutional systems of care. At the heart of our success you`ll find a talented team of experts who have helped our customers bridge the gap between the business needs of their organization, and the application of technologies required to successfully manage them.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.feisystems.com
  • 9755 Patuxent Woods Drive Suite 300
    Columbia, MD USA 21046
  • Phone: 443.270.5100

Executives

Name Title Contact Details

Similar Companies

Inhibitex

Inhibitex, Inc. is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gilva Biotechnology

Gilva Biotechnology is a Belmont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nanostics

Nanostics is a precision health company focused on the development and commercialization of novel, non-invasive diagnostic tests for cancer and other diseases. Their core technology is an advanced liquid biopsy platform that can accurately diagnose can...

Arbutus Biopharma

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV, we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio.

Bellus Health

BELLUS Health is a clinical stage biotechnology company developing novel therapeutics for the treatment of chronic cough and other chronic disorders triggered by hypersensitization.